GC Biopharma Corp. (KRX:006280)
South Korea
· Delayed Price · Currency is KRW 139,200
-900 (-0.64%)
Last updated: Apr 29, 2026, 2:00 PM KST
GC Biopharma Ratios and Metrics
Market cap in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Apr '26 Apr 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Market Capitalization | 1,598,979 | 1,814,695 | 2,048,665 | 1,432,354 | 1,478,007 | 2,488,073 | Upgrade
|
| Market Cap Growth | 11.10% | -11.42% | 43.03% | -3.09% | -40.60% | -46.30% | Upgrade
|
| Enterprise Value | 2,707,115 | 2,959,257 | 3,129,049 | 2,368,951 | 2,204,898 | 3,075,936 | Upgrade
|
| Last Close Price | 140100.00 | 157420.53 | 177716.89 | 123165.91 | 125551.64 | 208663.39 | Upgrade
|
| PE Ratio | - | - | - | - | 22.58 | 20.19 | Upgrade
|
| Forward PE | 44.72 | 28.99 | 87.99 | 47.35 | 21.09 | 25.00 | Upgrade
|
| PS Ratio | 0.80 | 0.91 | 1.22 | 0.88 | 0.86 | 1.62 | Upgrade
|
| PB Ratio | 1.15 | 1.30 | 1.38 | 0.93 | 0.94 | 1.66 | Upgrade
|
| P/TBV Ratio | 1.64 | 1.86 | 1.94 | 1.34 | 1.33 | 2.31 | Upgrade
|
| P/FCF Ratio | 59.00 | 66.96 | - | - | 24.17 | 105.17 | Upgrade
|
| P/OCF Ratio | 16.08 | 18.25 | - | - | 12.40 | 19.75 | Upgrade
|
| PEG Ratio | - | 1.35 | 1.35 | 1.35 | 1.35 | 1.20 | Upgrade
|
| EV/Sales Ratio | 1.36 | 1.49 | 1.86 | 1.46 | 1.29 | 2.00 | Upgrade
|
| EV/EBITDA Ratio | 13.71 | 19.04 | 27.67 | 21.57 | 15.12 | 23.73 | Upgrade
|
| EV/EBIT Ratio | 24.65 | 43.64 | 97.66 | 69.86 | 27.32 | 41.72 | Upgrade
|
| EV/FCF Ratio | 99.89 | 109.20 | - | - | 36.05 | 130.02 | Upgrade
|
| Debt / Equity Ratio | 0.70 | 0.70 | 0.56 | 0.47 | 0.37 | 0.40 | Upgrade
|
| Debt / EBITDA Ratio | 6.32 | 6.32 | 7.32 | 6.59 | 3.95 | 4.68 | Upgrade
|
| Debt / FCF Ratio | 36.24 | 36.24 | - | - | 9.41 | 25.64 | Upgrade
|
| Net Debt / Equity Ratio | 0.67 | 0.67 | 0.54 | 0.43 | 0.30 | 0.27 | Upgrade
|
| Net Debt / EBITDA Ratio | 5.99 | 5.99 | 7.11 | 6.09 | 3.18 | 3.11 | Upgrade
|
| Net Debt / FCF Ratio | 34.37 | 34.37 | -9.41 | -7.91 | 7.57 | 17.06 | Upgrade
|
| Asset Turnover | 0.70 | 0.70 | 0.62 | 0.63 | 0.69 | 0.67 | Upgrade
|
| Inventory Turnover | 1.76 | 1.76 | 1.90 | 2.38 | 2.52 | 2.28 | Upgrade
|
| Quick Ratio | 0.40 | 0.40 | 0.55 | 0.58 | 0.96 | 1.13 | Upgrade
|
| Current Ratio | 1.20 | 1.20 | 1.56 | 1.20 | 1.81 | 1.97 | Upgrade
|
| Return on Equity (ROE) | -2.07% | -2.07% | -2.82% | -1.27% | 4.53% | 9.89% | Upgrade
|
| Return on Assets (ROA) | 1.48% | 1.48% | 0.74% | 0.82% | 2.02% | 2.00% | Upgrade
|
| Return on Invested Capital (ROIC) | 2.84% | 2.94% | 1.43% | 1.60% | 3.32% | 3.36% | Upgrade
|
| Return on Capital Employed (ROCE) | 3.70% | 3.70% | 1.60% | 1.90% | 4.10% | 3.90% | Upgrade
|
| Earnings Yield | -0.29% | -0.26% | -1.28% | -1.86% | 4.43% | 4.95% | Upgrade
|
| FCF Yield | 1.69% | 1.49% | -4.17% | -5.90% | 4.14% | 0.95% | Upgrade
|
| Dividend Yield | 1.07% | 0.95% | - | - | - | - | Upgrade
|
| Payout Ratio | - | - | - | - | 36.65% | 15.02% | Upgrade
|
| Total Shareholder Return | 1.06% | 0.95% | - | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.